SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin) are effective for T2DM and CKD; ongoing trials are examining their direct effects on NAFLD [16]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.